File this under “What controversy?”
Last week, Pfizer increased the list prices of its medicines in the United States by an average of 8.8 percent, according to an investor note by Morgan Stanley analyst David Risinger.
This marks the second time this year that the drug maker has substantially boosted prices for its prescription drugs. Back on Jan. 1, Pfizer raised prices by an average of 10.4 percent, Risinger pointed out.
However, he noted that these increases do not reflect any rebates or discounts. After taking those price breaks into account, in fact, Risinger estimated that the actual “net price growth” was slightly less than half of the increases in the list prices.